81 results
8-K
EX-99.1
AKRO
Akero Therapeutics Inc
10 May 24
Akero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
7:17am
and injury to liver cells, leading to inflammation and fibrosis, which can progress to cirrhosis, liver failure, cancer and eventually death. MASH
424B5
AKRO
Akero Therapeutics Inc
6 Mar 24
Prospectus supplement for primary offering
5:16pm
(%)
13 (68%***)
p<0.001, versus placebo (CMH)
Summary of Week 96 Changes in Key Noninvasive Measures of Liver Fibrosis and Injury
Measure
(LS Mean
424B5
AKRO
Akero Therapeutics Inc
4 Mar 24
Prospectus supplement for primary offering
5:21pm
;0.001, versus placebo (CMH)
Summary of Week 96 Changes in Key Noninvasive Measures of Liver Fibrosis and Injury
Measure
(LS Mean Change From
8-K
EX-99.2
AKRO
Akero Therapeutics Inc
4 Mar 24
Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study
7:55am
, no imputation) 15
Statistically Significant Improvements in Markers of Liver Injury Sustained Through Week 96 ALT AST LS Mean Percent Change from Baseline LS
8-K
EX-99.1
gjy10mlfp 2w9ve3rfy
4 Mar 24
Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study
7:55am
8-K
EX-99.1
ehjxnhfsifej piciv
29 Feb 24
Akero Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
7:15am
8-K
EX-99.1
hdgi04gksl
18 Dec 23
Akero Therapeutics Announces First Patients Dosed in Efruxifermin Phase 3 SYNCHRONY Program
7:08am
8-K
EX-99.1
q5g 7mlp1
13 Nov 23
Akero Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
7:15am
8-K
EX-99.2
yctuaj0x
10 Oct 23
Regulation FD Disclosure
8:04am
8-K
84j737
10 Oct 23
Regulation FD Disclosure
8:04am
8-K
EX-99.1
9v2vhiea5mgwh 6u4pg
10 Oct 23
Regulation FD Disclosure
8:04am
8-K
EX-99.1
9ao7z0qfs2801q9ah68i
11 Aug 23
Akero Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
6:09am
8-K
EX-99.2
xqhybqv8 xndda
5 Jun 23
Results of Operations and Financial Condition
8:05am
8-K
EX-99.1
hl7a06vqj31gxavi ba
5 Jun 23
Results of Operations and Financial Condition
8:05am
8-K
EX-99.1
fqr9k1 x0
15 May 23
Akero Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
7:19am